Isprelor Update

RNS Number : 6714U

Alliance Pharma PLC

16 May 2008

 



For immediate release

16 May 2008

ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

Isprelor Update

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, today announces an update on the outlook for Isprelor, its development product for the induction of labour.

Following discussions yesterday with the European regulatory authorities, the Company is re-evaluating the development plan for Isprelor. It now appears likely that results of the Phase III trials completed last year will be inadequate, alone, to support the application for registration.  

As a result the Company is re-assessing what additional work needs to be done, but it is now unlikely that the filing for registration will take place before 2011.

For further information: 

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Rebecca Skye Dietrich
Numis Securities	+ 44 (0) 20 7260 1000
David Poutney / Michael Meade

 

END

 

 

RESILFLVEEIRLIT